Antibodies, Monoclonal, Murine-DerivedImmunoconjugatesAntigens, CD30VincristinePrednisoneLymphoma, FollicularAntibodies, MonoclonalLymphoma, Large B-Cell, DiffuseNitrogen Mustard CompoundsCyclophosphamideAntineoplastic Combined Chemotherapy ProtocolsDoxorubicinLymphoma, Mantle-CellLymphoma, Large-Cell, AnaplasticHodgkin DiseaseTreatment OutcomeAntigens, CD20CardiotoxinsLymphoma, Non-HodgkinDisease-Free SurvivalAntineoplastic AgentsImmunologic FactorsLymphoma, Primary EffusionRecurrenceHematologic NeoplasmsPeripheral Nervous System DiseasesClinical Trials, Phase I as TopicLymphoma, B-CellAnemia, RefractoryRefractory Period, ElectrophysiologicalRemission InductionOligopeptidesSalvage TherapyVidarabineAntirheumatic AgentsDrug Administration ScheduleLeukemia, Lymphocytic, Chronic, B-CellB-LymphocytesAnemia, Hemolytic, AutoimmunePurpura, Thrombocytopenic, IdiopathicDrug Therapy, CombinationAnemia, Refractory, with Excess of BlastsImmunosuppressive AgentsAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisWaldenstrom MacroglobulinemiaInfusions, IntravenousLymphocyte DepletionDrug Resistance, NeoplasmFollow-Up StudiesCombined Modality TherapyTransplantation, AutologousBoronic AcidsPrednisolonePyrazinesSurvival AnalysisRetrospective StudiesDose-Response Relationship, DrugPlasmapheresisTime FactorsArthritis, RheumatoidCytarabineAntibodies, Monoclonal, HumanizedImmunotherapyDrug ResistanceEtoposideCryoglobulinemiaSurvival RateAntibody-Dependent Cell CytotoxicityPlasma ExchangeMethotrexateMethylprednisoloneLymphoproliferative DisordersRadioimmunotherapyChillsLymphomaYttrium RadioisotopesThalidomideRetreatmentMitoxantroneCladribineTreatment FailureImmunoglobulins, IntravenousThrombocytopeniaDexamethasoneNeoplasm Recurrence, LocalAntibodies, NeoplasmKaplan-Meier EstimatePrognosisAntigens, CD19Stem Cell TransplantationMaximum Tolerated DoseSplenectomyReceptors, IgGNeutropeniaDisease ProgressionProspective StudiesNephrotic SyndromeGlomerulonephritis, MembranousVasculitisBiosimilar Pharmaceuticals